MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 563588 | Name: EGFR-IN-451

Description:

WARNING: This product is for research use only, not for human or veterinary use.

EGFR-IN-451 is an EGFR inhibitor, attenuating Ang II-induced Kidney Fibrosis.

Chemical Structure

EGFR-IN-451
EGFR-IN-451
CAS#220576-72-7

Theoretical Analysis

MedKoo Cat#: 563588

Name: EGFR-IN-451

CAS#: 220576-72-7

Chemical Formula: C19H15N5O

Exact Mass: 329.1277

Molecular Weight: 329.36

Elemental Analysis: C, 69.29; H, 4.59; N, 21.26; O, 4.86

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
EGFR-IN-451; EGFR IN 451; EGFRIN451; EGFR inhibitor 451; EGFR-inhibitor-451;
IUPAC/Chemical Name
N-[4-(1H-Indol-5-ylamino)-quinazolin-6-yl]-acrylamide
InChi Key
ZEPDLDKXAUOXBS-UHFFFAOYSA-N
InChi Code
InChI=1S/C19H15N5O/c1-2-18(25)23-14-4-6-17-15(10-14)19(22-11-21-17)24-13-3-5-16-12(9-13)7-8-20-16/h2-11,20H,1H2,(H,23,25)(H,21,22,24)
SMILES Code
C=CC(NC1=CC2=C(NC3=CC4=C(NC=C4)C=C3)N=CN=C2C=C1)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 329.36 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Ouyang X, Barling A, Lesch A, Tyner JW, Choonoo G, Zheng C, Jeng S, West TM, Clayburgh D, Courtneidge SA, McWeeney SK, Kulesz-Martin M. Induction of anaplastic lymphoma kinase (ALK) as a novel mechanism of EGFR inhibitor resistance in head and neck squamous cell carcinoma patient-derived models. Cancer Biol Ther. 2018 Jun 1:1-37. doi: 10.1080/15384047.2018.1451285. [Epub ahead of print] PubMed PMID: 29856687. 2: Quesada PR, Esteban LL, García JR, Sánchez RV, García TM, Alonso-Vega GG, Ferrández JS. Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients. Int J Clin Pharm. 2015 Oct;37(5):865-72. doi: 10.1007/s11096-015-0132-1. Epub 2015 May 26. PubMed PMID: 26008219. 3: Liang D, Zhong P, Hu J, Lin F, Qian Y, Xu Z, Wang J, Zeng C, Li X, Liang G. EGFR inhibition protects cardiac damage and remodeling through attenuating oxidative stress in STZ-induced diabetic mouse model. J Mol Cell Cardiol. 2015 May;82:63-74. doi: 10.1016/j.yjmcc.2015.02.029. Epub 2015 Mar 7. PubMed PMID: 25758431. 4: Chen L, Zhang M, Luo S. Outcome of gemcitabine plus molecular targeted agent for treatment of pancreatic cancer: a meta-analysis of prospective phase III studies. Tumour Biol. 2014 Nov;35(11):11551-8. doi: 10.1007/s13277-014-2451-6. Epub 2014 Aug 17. PubMed PMID: 25129442. 5: Gao Y, Davies SP, Augustin M, Woodward A, Patel UA, Kovelman R, Harvey KJ. A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. Biochem J. 2013 Apr 15;451(2):313-28. doi: 10.1042/BJ20121418. PubMed PMID: 23398362. 6: Wang Z, Zhang X, Bai H, Zhao J, Zhuo M, An T, Duan J, Yang L, Wu M, Wang S, Wang Y, Wu Y, Wang J. EML4-ALK rearrangement and its clinical significance in Chinese patients with advanced non-small cell lung cancer. Oncology. 2012;83(5):248-56. doi: 10.1159/000341381. Epub 2012 Sep 4. PubMed PMID: 22964709. 7: Blank SV, Christos P, Curtin JP, Goldman N, Runowicz CD, Sparano JA, Liebes L, Chen HX, Muggia FM. Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment. Gynecol Oncol. 2010 Dec;119(3):451-6. doi: 10.1016/j.ygyno.2010.08.008. Epub 2010 Sep 15. PubMed PMID: 20837357; PubMed Central PMCID: PMC3446254. 8: Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczésna A, Juhász E, Esteban E, Molinier O, Brugger W, Melezínek I, Klingelschmitt G, Klughammer B, Giaccone G; SATURN investigators. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010 Jun;11(6):521-9. doi: 10.1016/S1470-2045(10)70112-1. Epub 2010 May 20. PubMed PMID: 20493771. 9: Peng J, Jordan VC. Expression of estrogen receptor alpha with a Tet-off adenoviral system induces G0/G1 cell cycle arrest in SKBr3 breast cancer cells. Int J Oncol. 2010 Feb;36(2):451-8. PubMed PMID: 20043081; PubMed Central PMCID: PMC2842990. 10: Thomson S, Petti F, Sujka-Kwok I, Epstein D, Haley JD. Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy. Clin Exp Metastasis. 2008;25(8):843-54. doi: 10.1007/s10585-008-9200-4. Epub 2008 Aug 12. PubMed PMID: 18696232. 11: Montezano AC, Callera GE, Yogi A, He Y, Tostes RC, He G, Schiffrin EL, Touyz RM. Aldosterone and angiotensin II synergistically stimulate migration in vascular smooth muscle cells through c-Src-regulated redox-sensitive RhoA pathways. Arterioscler Thromb Vasc Biol. 2008 Aug;28(8):1511-8. doi: 10.1161/ATVBAHA.108.168021. Epub 2008 May 8. PubMed PMID: 18467645.